Outcomes stratified by a patient’s BCR-ABL1 level at 3 months in subgroups of >10%, ≤10% to >1%, and ≤1%. (A) Cumulative incidence for achievement of MMR, excluding 29 patients who achieved MMR prior to day 100. The differences among the 3 groups are statistically significant; P < .001 for each pairwise comparison. (B) OS by Kaplan-Meier method and (C) TFS. The survival differences among the 3 groups did not reach statistical significance for the survival analyses.